Yahoo
NasdaqGS - Delayed Quote USD

Geron Corporation (GERN)

1.5700 +0.0600 (+3.97%)
At close: September 4 at 4:00:01 PM EDT
1.5691 -0.0009 (-0.06%)
After hours: September 4 at 7:48:32 PM EDT
Trade Geron on Coinbase
Chart Range Bar
Loading chart for GERN

What's happening with GERN?

25m ago
Powered by Yahoo Scout

Geron Corporation is gaining attention with upcoming investor presentations and strong revenue growth for its drug RYTELO, while also managing risks related to reliance on a single product and financing needs.

Powered by Yahoo Scout
  • Previous Close 1.5100
  • Open 1.4900
  • Bid 1.3400 x 100
  • Ask 1.8200 x 100
  • Day's Range 1.4600 - 1.5900
  • 52 Week Range 1.0400 - 2.0100
  • Volume 11,477,760
  • Avg. Volume 11,784,506
  • Market Cap (intraday) 1.009B
  • Beta (5Y Monthly) 0.61
  • PE Ratio (TTM) --
  • EPS (TTM) -0.1100
  • Earnings Date Nov 4, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 4.25

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

www.geron.com

258

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

GERN
18.94%
S&P 500 (^GSPC)
12.75%

1-Year Return

GERN
13.77%
S&P 500 (^GSPC)
18.71%

3-Year Return

GERN
36.69%
S&P 500 (^GSPC)
70.93%

5-Year Return

GERN
9.03%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 57.48M
Earnings -16.68M
Profit Margin -29.02%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-20M
0
20M
40M
-60.0%
-50.0%
-40.0%
-30.0%
-20.0%
-10.0%

Analyst Insights

View More

Top Analyst

Needham
55/100
Latest Rating
Buy

Analyst Price Targets

3.00
4.25 Average
1.5700 Current
6.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 11/5/2025
Analyst Needham
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 5 -> 4

Statistics

View More

Valuation Measures

Annual
As of 9/1/2026
  • Market Cap

    1.02B

  • Enterprise Value

    842.83M

  • Trailing P/E

    --

  • Forward P/E

    79.37

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.84

  • Price/Book (mrq)

    4.35

  • Enterprise Value/Revenue

    3.77

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -33.05%

  • Return on Assets (ttm)

    -4.11%

  • Return on Equity (ttm)

    -28.28%

  • Revenue (ttm)

    204.56M

  • Net Income Avi to Common (ttm)

    -67.61M

  • Diluted EPS (ttm)

    -0.1100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    300.85M

  • Total Debt/Equity (mrq)

    55.87%

  • Levered Free Cash Flow (ttm)

    -78.37M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

1.5700 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: